IOVA Iovance Biotherapeutics, Inc.
Healthcare$4.10-0.24%ClosedMarket Cap: $1.47B
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
2.38
P/S
5.14
EV/EBITDA
-4.04
DCF Value
$4.06
FCF Yield
-20.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
114.5%
Operating Margin
-127.2%
Net Margin
-123.9%
ROE
-50.2%
ROA
-38.2%
ROIC
-45.3%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $71.4M | 98.6% | $-81.0M | $-79.0M | $— | — |
| Q4 null | $86.8M | 215.9% | $-73.5M | $-71.9M | $— | — |
| FY null | $263.5M | 97.2% | $-403.4M | $-391.0M | $— | — |
| Q3 null | $67.5M | 97.9% | $-94.9M | $-91.3M | $— | — |
| Q2 null | $60.0M | 5.5% | $-113.8M | $-111.7M | $— | — |
| Q1 null | $49.3M | -0.8% | $-121.2M | $-116.2M | $— | — |
| Q4 null | $73.7M | 38.2% | $-86.6M | $-78.6M | $— | — |
| FY null | $164.1M | 24.4% | $-395.3M | $-372.2M | $— | — |
| Q3 null | $58.6M | 32.0% | $-89.1M | $-83.5M | $— | — |
| Q2 null | $31.1M | -0.8% | $-101.9M | $-97.1M | $— | — |
| Q1 null | $715.0K | -915.5% | $-117.7M | $-113.0M | $— | — |
| Q4 2023 | $482.0K | -805.6% | $-121.3M | $-116.4M | $-0.45 | — |